Get started
Author

Didier Verhoeven

Observed names: D M E C Verhoeven, D Verhoeven, D. VERHOEVEN, D. Verhoeven, D.M. Verhoeven, D.M.E.C. Verhoeven, DTH Verhoeven, VERHOEVEN, Didier, Verhoeven, Didier
Observed institutions: Cliniques Universitaires Saint-Luc, University of Antwerp, University of Liège, Charles University, Leiden University Medical Center, Institut Gustave Roussy, AZ Klina, Centre Georges François Leclerc, Antwerp University Hospital, Centre Léon Bérard, Hôpital de Jolimont, Centre Eugène Marquis, Hospital Nossa Senhora da Conceição, Centre François Baclesse, Iridium Kankernetwerk, Centre Hospitalier Interrégional Edith Cavell, Instituto Nacional del Cáncer, Mayo Clinic in Florida, Institut du Cerveau, Institut Jean Godinot, AZ Sint-Blasius, Hospital of Prato, Institut Curie, UCLouvain, KU Leuven
ORCID: 0000-0002-7748-0837
Observed ORCID: 0000-0002-7748-0837
OpenAlex ID: A5026842240
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
2010 · Angelo Di Leo, Guy Jerusalem, et al. · Journal of Clinical Oncology · 634
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
2013 · A. D. Leo, G. Jerusalem, et al. · JNCI Journal of the National Cancer Institute · 322
PDF
Vitamins C and E, retinol, beta-carotene and dietary fibre in relation to breast cancer risk: a prospective cohort study
1997 · DTH Verhoeven, N Assen, et al. · British Journal of Cancer · 188
PDF
The Lancet Breast Cancer Commission
2024 · Charlotte E Coles, Helena Earl, et al. · The Lancet · 182
PDF
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
2012 · E. Seront, S. Rottey, et al. · Annals of Oncology · 126
PDF
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
2017 · Marco Colleoni, Weixiu Luo, et al. · The Lancet Oncology · 122
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
2020 · Lowell L. Hart, Renata Ferrarotto, et al. · Advances in Therapy · 114
PDF
Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas
1995 · P.B. Vermeulen, D. Verhoeven, et al. · Annals of Oncology · 106
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
2021 · Lori J. Goldstein, Mauro Mansutti, et al. · Breast Cancer Research and Treatment · 94
PDF
Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer
2008 · Jean-Pascal Machiels, Filomena Mazzeo, et al. · Journal of Clinical Oncology · 89
PDF
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 87
PDF
Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study
1995 · PB Vermeulen, D Verhoeven, et al. · British Journal of Cancer · 76
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
2015 · J. Vansteenkiste, F. Barlesi, et al. · Annals of Oncology · 72
PDF
Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial
2018 · Patrick Neven, Lynn Jongen, et al. · Clinical Cancer Research · 62
PDF
Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice
2019 · Carlos A. Garcia-Etienne, Robert E. Mansel, et al. · The Breast · 44
PDF
Comparison of cell growth in different parts of breast cancers
1990 · D. VERHOEVEN, N. BOURGEOIS, et al. · Histopathology · 38
Desmin-positive stellate cells associated with angiogenesis in a tumour and non-tumour system
1987 · Didier Verhoeven, Norbert Buyssens · Virchows Archiv B Cell Pathology Including Molecular Pathology · 36
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
2010 · Laetitia Gerlier, Mark Lamotte, et al. · BMC Cancer · 25
PDF
Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
2012 · A Di Leo, G Jerusalem, et al. · Cancer Research · 23
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group
2015 · Ignace Vergote, Philip Debruyne, et al. · Gynecologic Oncology · 22
Breast Cancer: global quality care optimizing care delivery with existing financial and personnel resources
2019 · Didier Verhoeven, Claudia Allemani, et al. · ESMO Open · 21
PDF
Radiation Therapy for in Situ or Localized Breast Cancer
1993 · D Verhoeven, E Van Marck, et al. · New England Journal of Medicine · 21
CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.
2009 · A. Di Leo, G. Jerusalem, et al. · Cancer Research · 20
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
2013 · Sally Anne Garnett, Miguel Martin, et al. · Breast Cancer Research and Treatment · 19
PDF
The presence of a type IV collagen skeleton associated with periductal elastosis in breast cancer.
1990 · D Verhoeven, N Bourgeois, et al. · Journal of Histochemistry & Cytochemistry · 16
Works count: 139
Citation count: 2,890
H-index: 21
I10-index: 32
Year
Topic
Type